Schedule
New Patients Referring Physicians
1-888-663-3488
Find a Doctor
Locations
Careers
Patient Portal
Log In Enroll
English
English Spanish
Donate

Ignacio Wistuba, MD

Ignacio Wistuba

Ignacio Wistuba, MD

Department Chair, Translational Pathology
Program Lead, Translational Pathology
Chair, Translational Pathology

Program: Translational Pathology

Language(s): English

1-888-663-3488

Insurance Coverage Information

Schedule appointment

  • Publications

    • Muneer A, Showkatian E, Saad MB, Hong L, Li S, Salehjahromi M, Aminu M, Sujit SJ, Xu H, Waqas M, Zafar A, Shroff G, Wu CC, Carter BW, Chang JY, Liao Z, Altan M, Vokes NI, Cascone T, Le X, Haymaker CL, Wistuba II, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Lou Y, Heymach JV, Zhang J, Wu J. Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study. Cancer Lett. 2026 Sep.656:218687. Pubmedid: 42314966.
    • Patel SA, Heald JL, Nead M, Singer B, Eapen GA, Farjah F, Kelly K, Kim ES, Mani H, Osarogiagbon RU, Pastis NJ, Pannu JK, Scholl L, Sears CR, Silvestri GA, Smith RA, Suh RD, Wood D, DiJulio TA, Johnson BE, Wistuba II, Rivera MP. The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer. Cancer. 2026 May.132(10):e70384. Pubmedid: 42118609.
    • Sells J, Clemente LC, Farris DP, Sizemore ML, Wistuba II, Soundararajan R, Raso MG. Enhancing Pathology Knowledge for Biomedical Scientists: Pilot Cohort Study of a Comprehensive Self-Paced Tutorial for Bridging Fundamental Concepts With Translational Applications. JMIR Med Educ. 2026 May.12:e84903. Pubmedid: 42166621. Pmcid: PMC13193296.
    • Houry M, Silva SJ, Artola M, Behrens C, Politi K, Wistuba I, Montuenga L, Exposito F, Calvo A. Loss of PTEN as an Independent Poor Prognosis Indicator in Lung Adenocarcinoma, but Not in Squamous Cell Carcinoma, Is Associated with an Immunosuppressive Tumor Microenvironment and Distinct Co-Mutational Profiles. Med Sci (Basel). 2026 May.14(2). Pubmedid: 42201046. Pmcid: PMC13214857.
    • Marques-Piubelli ML, Lima CFP, Lawson BC, Pandurengan R, Batra S, Duenas DE, Parra ER, Rodriguez S, Wistuba II, Ramalingam P, Malpica A, Euscher ED. Extrauterine mesonephric-like carcinoma: a tumor with a cold lymphocytic immune microenvironment. Virchows Arch. 2026 May. Pubmedid: 42159715.
    • Bontekoe E, Zhang M, Jiang P, Montoya A, Shulga Y, Slone JK, Paul E, Polera C, Forward S, Nassif Rausseo B, Assita ER, Xing C, Molkentine DP, Morris BB, Polic I, Roszik J, Salgado R, Vaishnavi A, Deniger D, Tran HT, Gibbons DL, Vaporciyan A, Gillison ML, Wistuba II, Kavraki LE, Zhang J, Lizee G, Yee C, Hwu P, Kwok S, Jaeger AM, Heymach JV, Reuben A. FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer. Cancer Immunol Res. 2026 Jun.14(6):958-973. Pubmedid: 41854516. Pmcid: PMC13119620.
    • Zhang M, Rausseo BN, Jiang P, Bontekoe E, Alves AM, Slone J, Rinsurongkawong W, Rinsurongkawong V, Patel A, Lewis J, Davies M, Hwu P, Lee J, Wistuba I, Vaporciyan A, Deniger D, Lizee G, Yee C, Kavraki L, Gibbons D, Tran H, Zhang J, Heymach J, Reuben A. Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinations. Res Sq. 2026 Jun. Pubmedid: 42370266. Pmcid: PMC13308340.
    • Dacic S, Shenker D, Redman M, Brunner L, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Brosnan-Cashman J, Hennek S, Grullon S, Posadas J, Fujimoto J, Connolly C, Wynes MW, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson AG, Schalper KA, Tsao MS, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA, Kris MG, Travis W, Yu L, Wistuba I. Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project. J Thorac Oncol. 2026 Jun.103953. Pubmedid: 42229633.
    • Naing A, Li X, Wang Q, Tian XJ, Sabir S, Bhosale PR, Derbala MH, Stephen B, Xu M, Hajjar J, Gurses SA, Yang Y, Momin HA, Wistuba II, Alshawa A, Shaw KR, Zarifa A, Singh G, Pandurengan RK, Raso GM, Parra ER, Song J, Mohammad MM, Rodon Ahnert J, Fu S, Subbiah V, Piha-Paul SA, Wang J, Woodman SE, Meric-Bernstam F. Biomarker study of pembrolizumab in patients with advanced rare cancers. Cell Rep Med. 2026 Jun.7(6):102827. Pubmedid: 42167248. Pmcid: PMC13293929.
    • Meyer ML, Peters S, Borghaei H, Cascone T, Dacic S, Faivre-Finn C, Leighl N, Paz-Ares L, Aerts J, Aggarwal C, Ahn MJ, Arcila ME, Ardizzoni A, Arrieta O, Awad MM, Bar J, Barlesi F, Bazhenova L, Besse B, Chaft J, Cho BC, Curioni Fontecedro A, DE Ruysscher D, Dingemans AM, Dziadziuszko R, Felip E, Forde P, Gandara DR, Garassino MC, Garcia Campelo R, Garrido Lopez P, Gautschi O, Girard N, Goto Y, Gray J, Hendriks L, Hirsch F, Hui R, Janne PA, Kerr K, Khorshid O, Pechoux CLE, Leal T, Lin JJ, Linardou H, Liu S, Mahrous M, Malapelle U, Mercadante E, Mitsudomi T, Mok T, Mountzios G, Naidoo J, Normanno N, Novello S, Oliveira J, Pappagallo G, Perrone G, Pérol M, Raez LE, Ramella S, Rami-Porta R, Reckamp K, Reguart Aransay N, Remon Masip J, Ricardi U, Ricciuti B, Rodriguez-Abreu D, Rotow JK, Santos ES, Schalper K, Senan S, Seto T, Skoulidis F, Smit EF, Soares M, Solli P, Solomon B, Soo RA, Stahel R, Stiles BM, VAN Schil P, Veronesi G, Wistuba II, Wolf J, Wu YL, Zer A, Rolfo C, Landi L, Cappuzzo F. Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC. J Thorac Oncol. 2026 Jul.104111. Pubmedid: 42532338.
    • Ding Q, Aung PP, Sun H, Soto LMS, Lu W, Raso MG, Rizvi YQ, Wistuba II, Sahin AA, Prieto VG. Upregulation of MMP9 expression in postradiation angiosarcoma of the breast: a possible predictive risk factor. Virchows Arch. 2026 Jul.489(1):199-204. Pubmedid: 40335788.
    • Treekitkarnmongkol W, Katayama H, Sankaran D, Tai MC, Rauth S, Chen H, Nguyen T, Hara K, Thege FI, Ponnusamy MP, Batra SK, Wang H, Wistuba II, Schmittgen TD, Heymach JV, Kopetz S, Hu T, Yao W, Maitra A, Sen S. RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. Nat Cell Biol. 2026 Jan.28(1):197-206. Pubmedid: 41326795. Pmcid: PMC13436838.
    • Peng F, Sinjab A, Dai Y, Treekitkarnmongkol W, Yang S, Gomez Bolanos LI, Zhou T, Chen M, Serrano AG, Krishna A, Karimi N, Sharma M, Basi A, Pei G, Liao J, Liu Y, Feng J, Rahal Z, Liu Y, Jiang J, Yu K, Noun T, Liu Y, Khan K, Cho KS, Chen J, Solis LM, Mazzilli S, Dubinett S, Cascone T, Spira AE, Swisher S, Jimbo N, Hayashi T, Kishikawa S, Takamochi K, Itoh T, Yao T, Suzuki K, Kalhor N, Wistuba II, Li M, Moghaddam SJ, Fujimoto J, Burks J, Myers J, Akdemir K, Wang L, Kadara H. Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions. Cancer Cell. 2026 Feb.44(2):321-339.e13. Pubmedid: 41202811. Pmcid: PMC12980502.
    • Hofman V, Rignol G, Mograbi B, Ilié M, Riudavets M, Lopez-Rios F, Fusco N, Malapelle U, Popat S, Stenzinger A, Planchard D, Passaro A, Heeke S, Peters S, Wistuba II, Hirsch FR, Hofman P. New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective. Lung Cancer. 2026 Aug.218:109507. Pubmedid: 42364305.
    • Ozirmak Lermi N, Molina Ayala M, Hernandez S, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples. Nat Commun. 2025 Sep.16(1):8499. Pubmedid: 41006245. Pmcid: PMC12474935.
    • Wen PY, Manzanera A, Duault C, Gonzalez-Kozlova E, Lopez L, Grossman SA, Ye X, Fisher J, Lee I, Walbert T, Snyder J, Brem S, Desai A, Bagley SJ, Kakani C, Strowd R, Tatter S, Laxton A, Lesser G, Amankulor N, Lieberman F, Drappatz J, Mantica M, Triggs D, Haymaker C, Wistuba II, Al-Atrash G, Mendoza Perez J, Futreal A, Little LD, Islam MDH, Duose D, Jiang P, Reuben A, Lawler SE, Pichavant M, Gentles A, Bendall S, Kong A, Camacho C, Del Valle D, Kim-Schulze S, Gnjatic S, Sharon E, Nowicki MO, Peruzzi P, Lane D, Aguilar-Cordova E, Aguilar LK, Nichols G, Dwyer J, Tak PP, Maecker H, Barone F, Chiocca EA. A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma. Neurooncol. 2025 Oct.27(10):2617-2631. Pubmedid: 40120123. Pmcid: PMC12833529.
    • Li H, Hong L, Rocha P, Bach R, Solis Soto LM, Rinsurongkawong W, Zhang B, Araujo HA, Elamin YY, Altan M, Arrechedera CA, Zhou J, Khan KB, Lu W, Young E, Gay CM, Cascone T, Byers LA, Skoulidis F, Blumenschein G, Fossella FV, Tsao A, Negrao MV, Vokes N, Wu J, Tran HT, Wistuba II, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Le X, Zhang J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers (Basel). 2025 Nov.17(23). Pubmedid: 41375002. Pmcid: PMC12691313.
    • Zhu Y, Solis Soto LM, Pant S, Vega EA, Vinuela E, Bozorgui B, Vauthey JN, Aguayo G, Wang Z, Lu W, Chen X, Mino B, Kakarala L, Dai J, Liu S, Wani KM, Lazar AJ, Carapeto F, Lee S, Wistuba I, Korkut A, Javle M, Kwong LN. Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance. Mod Pathol. 2025 Nov.38(11):100824. Pubmedid: 40541865.
    • Tsao MS, Sholl L, Shiller M, Illei P, Wistuba II, Beasley MB, Schalper KA, Simmons A, Ansell P, Beruti S, Mino-Kenudson M. MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer. NPJ Precis Oncol. 2025 Nov.9(1):369. Pubmedid: 41266553. Pmcid: PMC12635195.
    • Soeung M, Yan X, Zanca C, Qian J, Karki M, Duan F, Khan H, Zhang L, Peng DH, Williams M, He R, Chen Z, Perelli L, Chen J, Tidwell RS, Chauhan PK, Le CN, Lam TNA, Bhattacharya N, Shah R, Ho IL, Gay JP, Carrillo CC, Feng N, Le K, Gao G, Perry TL, Mseeh F, Jiang Y, Xu QA, Zacharias NM, Sheth RA, Bathala TK, Rao P, Daw NC, Tripathi DN, Walker CL, Mohammad MM, Zhang J, Han G, Chu Y, Wang R, Dang M, Dai E, Peng F, Liu Y, Jadhav A, Lang W, Arrechedera CA, Clemente LC, Parra ER, Lu H, Haymaker CL, Wistuba II, Futreal A, Viale A, Soth MJ, Jones P, Marszalek JR, Heffernan T, Draetta GF, Tannir NM, Gao J, Wang L, Genovese G, Msaouel P. Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence. Nat Commun. 2025 Nov.16(1):10474. Pubmedid: 41290625. Pmcid: PMC12647744.
    • Morris VK, Liu S, Lin K, Zhu H, Prasad S, Mahvash A, Bhosale P, Sun B, Parra ER, Wistuba I, Peddireddy A, Yao J, Mendoza-Perez J, Knafl M, Woodman SE, Eng C, Halperin D. Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. Clin Cancer Res. 2025 May.31(9):1657-1666. Pubmedid: 40019482. Pmcid: PMC12010964.
    • Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. N ...
    • Chou TY, Dacic S, Wistuba I, Beasley MB, Berezowska S, Chang YC, Chung JH, Connolly C, Han Y, Hirsch FR, Hwang DM, Janowczyk A, Joubert P, Kerr KM, Lin D, Minami Y, Mino-Kenudson M, Nicholson AG, Papotti M, Rekhtman N, Roden AC, von der Thüsen JH, Travis W, Tsao MS, Yatabe Y, Yeh YC, Bubendorf L, Chang WC, Denninghoff V, Fernandes Tavora FR, Hayashi T, Hofman P, Jain D, Kim TJ, Lantuejoul S, Le Quesne J, Lopez-Rios F, Matsubara D, Noguchi M, Radonic T, Saqi A, Schalper K, Shim HS, Sholl L, Weissferdt A, Cooper WA. Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2025 Mar.20(3):311-330. Pubmedid: 39579981.
    • Mitchell KG, Lee Y, Deboever N, Negrao MV, Tran HT, Parra E, Byers L, Reuben A, Federico L, Bernatchez C, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, McGrail DJ, Sepesi B, Haymaker CL. Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer. J Immunother Cancer. 2025 Jun.13(6). Pubmedid: 40555561. Pmcid: PMC12198785.
    • Patel SP, Fisher J, Chae YK, Soto LS, Kasi A, Konda B, Walshauser M, Parra E, Zhang J, Duault C, Gonzalez-Kozlova E, Manyam G, Zhang J, Chen H, Duose DY, Laberiano Fernandez C, Luthra R, Al-Atrash G, Kim-Schulze S, Maecker HT, Wistuba II, Gnjatic S, Lee JJ, Zhang J, Magner CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke C, Haymaker CL, Kurzrock R. Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort. J Immunother Cancer. 2025 Jun.13(6). Pubmedid: 40588371. Pmcid: PMC12211841.
    • Zhu B, Chen P, Aminu M, Li JR, Fujimoto J, Tian Y, Hong L, Chen H, Hu X, Li C, Vokes N, Moreira AL, Gibbons DL, Solis Soto LM, Parra Cuentas ER, Shi O, Diao S, Ye J, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Nilsson M, Huang B, Heeke S, Zhang J, Haymaker CL, Velcheti V, Sterman DH, Kochat V, Padron WI, Alexandrov LB, Wei Z, Le X, Wang L, Fukuoka J, Lee JJ, Wistuba II, Pass HI, Davis M, Hanash S, Cheng C, Dubinett S, Spira A, Rai K, Lippman SM, Futreal PA, Heymach JV, Reuben A, Wu J, Zhang J. Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer Cell. 2025 Jun.43(6):1125-1140.e10. Pubmedid: 40345189. Pmcid: PMC12151776.
    • Yang D, Sun X, Wang H, Wistuba II, Wang H, Maitra A, Chen Y. TREM2 Depletion in Pancreatic Cancer Elicits Pathogenic Inflammation and Accelerates Tumor Progression via Enriching IL-1β+ Macrophages. Gastroenterology. 2025 Jun.168(6):1153-1169. Pubmedid: 39956331. Pmcid: PMC12103993.
    • Saad MB, Al-Tashi Q, Hong L, Verma V, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter BW, Shroff GS, Cascone T, Le X, Elamin YY, Altan M, Heeke S, Sheshadri A, Chang JY, Lee PP, Liao Z, Gibbons DL, Vaporciyan AA, Lee JJ, Wistuba II, Haymaker C, Mirjalili S, Jaffray D, Gainor JF, Lou Y, Di Federico A, Pecci F, Awad M, Ricciuti B, Heymach JV, Vokes NI, Zhang J, Wu J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun. 2025 Jul.16(1):6828. Pubmedid: 40707438. Pmcid: PMC12289920.
    • Thomas-Jardin S, Suresh S, Arce A, Novaresi N, Deng Q, Stein E, Thomas L, Lewis C, Ahn C, Evers BM, Akbay EA, Salvatierra ME, Lu W, Khan K, Solis Soto LM, Wistuba II, Minna JD, O'Donnell KA. The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer. Cancer Res. 2025 Jul.85(14):2574-2590. Pubmedid: 40327600. Pmcid: PMC12260515.
    • Taube JM, Sunshine JC, Angelo M, Akturk G, Eminizer M, Engle LL, Ferreira CS, Gnjatic S, Green B, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Jiménez-Sánchez D, Korski K, Lako A, Parra ER, Rebelatto MC, Rimm DL, Rodig SJ, Rodriguez-Canales J, Roskes JS, Schalper KA, Schenck E, Steele KE, Surace MJ, Szalay AS, Tetzlaff MT, Wistuba II, Yearley JH, Bifulco CB. Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. J Immunother Cancer. 2025 Jan.13(1). Pubmedid: 39779210. Pmcid: PMC11749220.
    • Bhamidipati D, Johnson JR, Lin K, Pelicano H, Eng C, Huey R, Wolff RA, Halperin DM, Frumovitz MF, Wistuba II, Duose DY, Mallampati S, Luthra R, Morris VK. The Clinical Utility of a Next-Generation Sequencing-Based Approach to Detecting Circulating HPV DNA in Patients with Advanced Anal Cancer. Cancers (Basel). 2025 Jan.17(2). Pubmedid: 39858090. Pmcid: PMC11764299.
    • Maher MH, Duose DY, Wistuba II, Luthra R, Arjuna S, Roy-Chowdhuri S. A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens. Cancer Cytopathol. 2025 Jan.133(1):e22925. Pubmedid: 39704279.
    • Lermi NO, Ayala MM, Ruiz SH, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. Res Sq. 2025 Jan. Pubmedid: 39877088. Pmcid: PMC11774462.
    • Dacic S, Abel J, Hennek SR, Travis WD, Wistuba II. A Response to the Letter to the Editor: "Performance Optimization of CNN Model Based on Attention Mechanism in Patients With NSCLC". J Thorac Oncol. 2025 Feb.20(2):e29-e30. Pubmedid: 39914929.
    • Roudko V, Del Valle DM, Radkevich E, Kelly G, Hui X, Patel M, Gonzalez-Kozlova E, Tuballes K, Streicher H, Atale S, Wang L, CzinCzin B, Kim-Schulze S, Wistuba II, Haymaker CL, Al-Atrash G, Manyam G, Zhang J, Thompson R, Suarez-Farinas M, Lheureux S, Gnjatic S. Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer. J Immunother Cancer. 2025 Feb.13(2). Pubmedid: 40010771. Pmcid: PMC11865721.
    • Bayraktar R, Tang Y, Dragomir MP, Ivan C, Peng X, Fabris L, Zhang J, Carugo A, Aneli S, Liu J, Chen MM, Srinivasan S, Sahnoune I, Bayraktar E, Akdemir KC, Chen M, Narayanan P, Huang W, Ott LF, Eterovic AK, Villarreal OE, Mohammad MM, Peoples MD, Walsh DM, Hernandez JA, Morgan MB, Shaw KR, Davis JS, Menter D, Tam CS, Yeh P, Dawson SJ, Rassenti LZ, Kipps TJ, Kunej T, Estrov Z, Joosse SA, Pagani L, Alix-Panabières C, Pantel K, Ferajoli A, Futreal A, Wistuba II, Radovich M, Kopetz S, Keating MJ, Draetta GF, Mattick JS, Liang H, Calin GA. The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers. Sci Adv. 2025 Feb.11(8):eado2830. Pubmedid: 39970212. Pmcid: PMC11837999.
    • Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2025 Dec.15(12):2574. Pubmedid: 41327972.
    • Rocha P, Bach R, Masfarré L, Hernandez S, Navarro-Gorro N, Rossell A, Villanueva X, Giner M, Sanchéz I, Galindo M, Del Rey-Vergara R, Iñañez A, Sanchéz-Espiridion B, Lu W, Acedo-Terrades A, Berenguer-Molins P, Sánchez-Font A, Chalela R, Curull V, Taus Á, Hardy-Werbin M, Sausen M, Georgiadis A, White J, Jackson JB, Moliner L, Clavé S, Bellosillo B, Rovira A, Wistuba I, Soto LMS, Perera-Bel J, Arriola E. Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade. Oncoimmunology. 2025 Dec.14(1):2469377. Pubmedid: 39991958. Pmcid: PMC11853546.
    • Sater S, Bifulco CB, Rodriguez-Canales J, Yeong J, Akturk G, Angelo M, Ballesteros-Merino C, Bankhead P, Basu S, Blando JM, Brajkovic S, Cassano M, Chen BJ, Coskun AF, Cottrell TR, De Andrea CE, Edwards RH, Egelston C, Engle LL, Ernstoff MS, Fan R, Feldman M, Fox BA, Galon J, Gartrell R, Gnjatic S, Green BF, Gulley JL, Hellebust A, Hewitt S, Hollmann TJ, Horn LA, Howat WJ, Hoyt CC, Jensen SM, Kulasinghe A, Lassoued W, Lott S, Mansfield J, Marwitz S, Netto G, Page DB, Parra E, Rimm DL, Rodig SJ, Salgado R, Schapiro D, Schalper KA, Sunshine JC, Surace MJ, Szalay AS, Thurin M, Villasboas JC, Wharton K, Wistuba II, Yearley JH, Yuan Y, Zaki G, Ziai J, Taube JM. Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI). J Immunother Cancer. 2025 Dec.13(12). Pubmedid: 41423269. Pmcid: PMC12718562.
    • Zullo L, Filippiadis D, Hendriks LEL, Portik D, Spicer JD, Wistuba II, Besse B. Lung metastases. Nat Rev Dis Primers. 2025 Aug.11(1):60. Pubmedid: 40841521.
    • Weathers SP, Li X, Zhu H, Damania AV, Knafl M, McKinley B, Lin H, Harrison RA, Majd NK, O'Brien BJ, Penas-Prado M, Loghin M, Kamiya-Matsuoka C, Yung WKA, Solis Soto LM, Maru DM, Wistuba I, Parra Cuentas ER, Hernandez S, Futreal A, Wargo JA, Schulze K, Darbonne WC, Ajami NJ, Woodman SE, de Groot JF. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial. Nat Commun. 2025 Apr.16(1):3950. Pubmedid: 40289138. Pmcid: PMC12034766.
    • Batra H, Bose PSC, Ding Y, Dai A, Chen H, Albarracin CT, Sun H, Sahin AA, Yang F, Wistuba II, Raso MG. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Histopathology. 2024 Sep.85(3):503-509. Pubmedid: 38973399.
    • Yang D, Sun X, Moniruzzaman R, Wang H, Citu C, Zhao Z, Wistuba II, Wang H, Maitra A, Chen Y. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Cell Rep Med. 2024 Sep.5(9):101711. Pubmedid: 39232498. Pmcid: PMC11525027.
    • Molina-Alejandre M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, Casarrubios M, Casal-Rubio J, Martinez-Martí A, Insa A, Massuti B, Viteri S, Barneto Aranda I, Rodriguez-Abreu D, de Castro J, Martínez JM, Cobo M, Wistuba II, Parra ER, Martín-López J, Megías D, Muñoz-Viana R, Garrido F, Aptsiauri N, Ruiz-Cabello F, Provencio M, Cruz-Bermúdez A. Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer. J Immunother Cancer. 2024 Oct.12(10). Pubmedid: 39428126. Pmcid: PMC11492944.
    • Anfossi S, Darbaniyan F, Quinlan J, Calin S, Shimizu M, Chen M, Rausseo P, Winters M, Bogatenkova E, Do KA, Martinez I, Li Z, Antal L, Olariu TR, Wistuba I, Calin GA. MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2. Mol Cancer. 2024 Oct.23(1):235. Pubmedid: 39434078. Pmcid: PMC11492698.
    • Li C, Nguyen TT, Li JR, Song X, Fujimoto J, Little L, Gumb C, Chow CB, Wistuba II, Futreal AP, Zhang J, Hubert SM, Heymach JV, Wu J, Amos CI, Zhang J, Cheng C. Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer. NPJ Precis Oncol. 2024 Oct.8(1):225. Pubmedid: 39369068. Pmcid: PMC11455871.
    • Thomas-Jardin S, Suresh S, Arce A, Novaresi N, Stein E, Thomas L, Lewis C, Ahn C, Evers BM, Salvatierra ME, Lui W, Khan K, Solis Soto LM, Wistuba I, Minna JD, O'Donnell KA. Coordinated translational control of multiple immune checkpoints by the integrated stress response pathway in lung cancer. bioRxiv. 2024 Oct. Pubmedid: 39554171. Pmcid: PMC11565990.
    • Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, Ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, Lu KH, Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S. Defining precancer: a grand challenge for the cancer community. Nat Rev Cancer. 2024 Nov.24(11):792-809. Pubmedid: 39354069.
    • Serrano AG, Rocha P, Freitas Lima C, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol. 2024 Nov.8(1):268. Pubmedid: 39558076. Pmcid: PMC11574146.
    • Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov.635( ...
    • Laberiano-Fernandez C, Gan Q, Wang SM, Tamegnon A, Wistuba I, Yoon E, Roy-Chowdhuri S, Parra ER. Exploratory pilot study to characterize the immune landscapes of malignant pleural effusions and their corresponding primary tumors from patients with breast carcinoma and lung adenocarcinoma. J Am Soc Cytopathol. 2024 May.13(3):161-173. Pubmedid: 38519275. Pmcid: PMC11969369.
    • Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez FR, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Cheng C, Lee JJ, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su D, Fukuoka J, Antonoff MB, Gerber DE, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Spira A, Futreal AP, Reuben A, Zhang J. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Res Sq. 2024 May. Pubmedid: 38798564. Pmcid: PMC11118701.
    • Cho WC, Saade R, Nagarajan P, Aung PP, Milton DR, Marques-Piubelli ML, Hudgens C, Ledesma D, Nelson K, Ivan D, Zhang M, Torres-Cabala CA, Campbell M, Alhalabi O, Prieto VG, Wistuba II, Esmaeli B, Curry JL. Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. J Cutan Pathol. 2024 May.51(5):360-367. Pubmedid: 38200650.
    • Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature. 2024 Mar.627(8004):656-663. Pubmedid: 38418883. Pmcid: PMC10954546.
    • Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024 Mar.187(7):1617-1635. Pubmedid: 38552610. Pmcid: PMC7616034.
    • Treekitkarnmongkol W, Solis LM, Sankaran D, Gagea M, Singh PK, Mistry R, Nguyen T, Kai K, Liu J, Sasai K, Jitsumori Y, Liu J, Nagao N, Stossi F, Mancini MA, Wistuba II, Thompson AM, Lee JM, Cadiñanos J, Wong KK, Abbott CM, Sahin AA, Liu S, Katayama H, Sen S. eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal. 2024 Mar.17(826):eadh4475. Pubmedid: 38442201. Pmcid: PMC12039992.
    • Salehjahromi M, Karpinets TV, Sujit SJ, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes NI, Behrens C, Siewerdsen JH, Hazle JD, Chang JY, Zhang J, Lu Y, Godoy MCB, Chung C, Jaffray D, Wistuba I, Lee JJ, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med. 2024 Mar.5(3):101463. Pubmedid: 38471502. Pmcid: PMC10983039.
    • Castaneda CA, Castillo M, Bernabe LA, Sanchez J, Fassan M, Tello K, Wistuba II, Chavez Passiuri I, Ruiz E, Sanchez J, Barreda F, Valdivia D, Bazan Y, Abad-Licham M, Mengoa C, Fuentes H, Montenegro P, Poquioma E, Alatrista R, Flores CJ, Taxa L. Association between Helicobacter pylori infection, mismatch repair, HER2 and tumor-infiltrating lymphocytes in gastric cancer. World J Gastrointest Oncol. 2024 Jun.16(6):2487-2503. Pubmedid: 38994161. Pmcid: PMC11236231.
    • Seth S, Chen R, Liu Y, Fujimoto J, Hong L, Reuben A, Varghese S, Behrens C, McDowell T, Soto LS, Haymaker C, Weissferdt A, Kalhor N, Wu J, Le X, Vokes NI, Cheng C, Heymach JV, Gibbons DL, Futreal PA, Wistuba II, Kadara H, Zhang J, Moran C, Zhang J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innov. 2024 Jun.3(3):e112. Pubmedid: 38947760. Pmcid: PMC11212327.
    • Yang D, Sun X, Moniruzzaman R, Wang H, Citu C, Zhao Z, Wistuba II, Wang H, Maitra A, Chen Y. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Gastroenterology. 2024 Jul.167(2):298-314. Pubmedid: 38467382. Pmcid: PMC11972442.
    • Yu D, Kane MJ, Koay EJ, Wistuba II, Hobbs BP. Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC. Sci Rep. 2024 Jul.14(1):15004. Pubmedid: 38951567. Pmcid: PMC11217297.
    • Wermke M, Holderried TAW, Luke JJ, Morris VK, Alsdorf WH, Wetzko K, Andersson BS, Wistuba II, Parra ER, Hossain MB, Grund-Gröschke S, Aslan K, Satelli A, Marisetty A, Satam S, Kalra M, Hukelmann J, Kursunel MA, Pozo K, Acs A, Backert L, Baumeister M, Bunk S, Wagner C, Schoor O, Mohamed AS, Mayer-Mokler A, Hilf N, Krishna D, Walter S, Tsimberidou AM, Britten CM. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024 Jul.12(7). Pubmedid: 39038917. Pmcid: PMC11268062.
    • Treekitkarnmongkol W, Shah V, Kai K, Katayama H, Wong J, Ladha FA, Nguyen T, Menegaz B, Lu W, Yang F, Mino B, Tang X, Gagea M, Batra H, Raso MG, Wistuba II, Krishnamurthy S, Pinder SE, Sawyer EJ, Thompson AM, Sen S. Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer. Brit J Cancer. 2024 Jul.131(1):171-183. Pubmedid: 38760444. Pmcid: PMC11231151.
    • Gonzalez-Kozlova E, Huang HH, Jagede OA, Tuballes K, Del Valle DM, Kelly G, Patel M, Xie H, Harris J, Argueta K, Nie K, Barcessat V, Moravec R, Altreuter J, Duose DY, Kahl BS, Ansell SM, Yu J, Cerami E, Lindsay JR, Wistuba II, Kim-Schulze S, Diefenbach CS, Gnjatic S. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. Cancer Res Commun. 2024 Jul.4(7):1726-1737. Pubmedid: 38934093. Pmcid: PMC11247952.
    • Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 2024 Feb.42(2):225-237.e5. Pubmedid: 38278149. Pmcid: PMC10982990.
    • Tai MC, Bantis LE, Parhy G, Kato T, Tanaka I, Chow CW, Fujimoto J, Behrens C, Hase T, Kawaguchi K, Fahrmann JF, Ostrin EJ, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Hanash SM, Wistuba II, Taguchi A. Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma. Int J Mol Sci. 2024 Feb.25(4). Pubmedid: 38397007. Pmcid: PMC10888571.
    • Marques-Piubelli ML, Navarrete J, Ledesma DA, Hudgens CW, Lazcano RN, Alani A, Huen A, Duvic M, Nagarajan P, Aung PP, Wistuba II, Curry JL, Miranda RN, Torres-Cabala CA. Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides. Cells. 2024 Feb.13(5). Pubmedid: 38474383. Pmcid: PMC10931377.
    • Roy-Chowdhuri S, Mani H, Fox AH, Tsao A, Sholl LM, Farjah F, Johnson BE, Osarogiagbon RU, Rivera MP, Silvestri GA, Smith RA, Wistuba II. The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer. Cancer. 2024 Dec.130(24):4200-4212. Pubmedid: 39347608. Pmcid: PMC11585344.
    • Ozirmak Lermi N, Molina Ayala M, Hernandez S, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q, Team R, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. bioRxiv. 2024 Dec. Pubmedid: 39763763. Pmcid: PMC11702517.
    • Lubo I, Hernandez S, Wistuba II, Solis Soto LM. Novel Spatial Approaches to Dissect the Lung Cancer Immune Microenvironment. Cancers (Basel). 2024 Dec.16(24). Pubmedid: 39766047. Pmcid: PMC11674389.
    • Fox AH, Osarogiagbon RU, Farjah F, Jett JR, Johnson BE, Rivera MP, Smith RA, Wistuba II, Silvestri GA. The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non-small cell lung cancer. Cancer. 2024 Dec.130(24):4188-4199. Pubmedid: 39347617. Pmcid: PMC11585345.
    • Kurzrock R, Chaudhuri AA, Feller-Kopman D, Florez N, Gorden J, Wistuba II. Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review. Cancer Metastasis Rev. 2024 Dec.43(4):1217-1231. Pubmedid: 38750337. Pmcid: PMC11554720.
    • Solórzano JL, Menéndez V, Parra E, Solis L, Salazar R, García-Cosío M, Climent F, Fernández S, Díaz E, Francisco-Cruz A, Khoury J, Jiang M, Tamegnon A, Montalbán C, Melero I, Wistuba I, De Andrea C, F García J. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. Oncoimmunology. 2024 Aug.13(1):2388304. Pubmedid: 39135889. Pmcid: PMC11318683.
    • Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER. Author Correction: TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2024 Aug.632(8024):E2. Pubmedid: 39030431.
    • de Sousa LG, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas EP, Cho WC, Wistuba I, Yao JC, Woodman SE, Halperin DM, Ferrarotto R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncol. 2024 Apr.151:106747. Pubmedid: 38460288.
    • Khanduri I, Maki H, Verma A, Katkhuda R, Anandappa G, Pandurengan R, Zhang S, Mejia A, Tong Z, Solis Soto LM, Jadhav A, Wistuba II, Menter D, Kopetz S, Parra ER, Vauthey JN, Maru DM. New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis. BJC Rep. 2024 Apr.2(1):37. Pubmedid: 39516662. Pmcid: PMC11523988.
    • Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr.5(4):625-641. Pubmedid: 38351182. Pmcid: PMC12955605.
    • Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst R, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial. Clin Cancer Res. 2024 Apr.30(8):1655-1668. Pubmedid: 38277235. Pmcid: PMC11016892.
    • Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. Author Correction: An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature. 2024 Apr.628(8006):E1. Pubmedid: 38499683. Pmcid: PMC10990920.
    • Perez-Oquendo M, Romano G, Farris DP, Gandhi V, Wistuba II, Tillman RE, Udan R, Mangahas P, Soundararajan R. A structured curriculum supporting biomedical trainees' transition into independent academic positions and early career success. BMC Med Educ. 2024 Apr.24(1):379. Pubmedid: 38589919. Pmcid: PMC11000405.
    • Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024 Apr.15(1):3152. Pubmedid: 38605064. Pmcid: PMC11009351.
    • Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel). 2023 Dec.16(1). Pubmedid: 38201434. Pmcid: PMC10778229.
    • Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012 May.118(9):2454-2465. Pubmedid: 21952750. Pmcid: PMC3298843.
    • He Y, Correa AM, Raso MG, Hofstetter WL, Fang B, Behrens C, Roth JA, Zhou Y, Yu L, Wistuba II, Swisher SG, Pataer A. The role of PKR/eIF2α signaling pathway in prognosis of non-small cell lung cancer. PLoS One. 2012 May.6(11):e24855. Pubmedid: 22102852. Pmcid: PMC3213082.
    • Vishwamitra D, Li Y, Wilson D, Manshouri R, Curry CV, Shi B, Tang XM, Sheehan AM, Wistuba II, Shi P, Amin HM. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am J Pathol. 2012 May.180(5):1772-1780. Pubmedid: 22414602. Pmcid: PMC3349824.
    • Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res. 2012 Mar.18(6):1641-1654. Pubmedid: 22275507. Pmcid: PMC3306446.
    • Moran CA, Weissferdt A, Kalhor N, Solis LM, Behrens C, Wistuba II, Suster S. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol. 2012 Mar.137(3):444-450. Pubmedid: 22338057.
    • Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar.18(5):1435-1446. Pubmedid: 22261807. Pmcid: PMC6167936.
    • Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Jun.118(11):2889-2899. Pubmedid: 22020674. Pmcid: PMC3369269.
    • He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012 Jul.7(2):e31087. Pubmedid: 22348039. Pmcid: PMC3277494.
    • William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan.23(1):78-85. Pubmedid: 21430184. Pmcid: PMC3276321.
    • Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res. 2012 Jan.18(1):127-139. Pubmedid: 22090359. Pmcid: PMC3251692.
    • Field JK, Smith RA, Aberle DR, Oudkerk M, Baldwin DR, Yankelevitz D, Pedersen JH, Swanson SJ, Travis WD, Wisbuba II, Noguchi M, Mulshine JL. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012 Jan.7(1):10-19. Pubmedid: 22173661.
    • Kadara H, Kabbout M, Wistuba II. Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology. 2012 Jan.17(1):50-65. Pubmedid: 22040022. Pmcid: PMC3911779.
    • Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb.104(3):228-239. Pubmedid: 22247021. Pmcid: PMC3274509.
    • Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 2012 Aug.118(16):3993-4003. Pubmedid: 22359227. Pmcid: PMC3674414.
    • Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba II, Behrens C, Timsit JF, Pio R, Field JK, Montuenga LM. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012 Apr.30(10):1129-1136. Pubmedid: 22355056. Pmcid: PMC4874209.
    • Tsuta K, Kalhor N, Wistuba II, Moran CA. Clinicopathological and immunohistochemical analysis of spindle-cell carcinoid tumour of the lung. Histopathology. 2011 Sep.59(3):526-536. Pubmedid: 22034892.
    • Kim MP, Chen Y, Bekele BN, Lopez A, Khanna A, Chen JQ, Spitz MR, Behrens C, Solis L, Wismach M, Ji L, Wistuba II, Roth JA, Katz RL. Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg. 2011 Sep.92(3):1044-1050. Pubmedid: 21871297. Pmcid: PMC3272351.
    • Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res. 2011 Sep.17(17):5705-5714. Pubmedid: 21742808. Pmcid: PMC3166982.
    • Zhang YA, Maitra A, Hsieh JT, Rudin CM, Peacock CD, Karikari C, Brekken RA, Stastny V, Gao B, Girard L, Wistuba I, Frenkel E, Minna JD, Gazdar AF. Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther. 2011 Oct.12(7):617-628. Pubmedid: 21750403. Pmcid: PMC3218386.
    • Ahn YH, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II, Lin W, Thilaganathan N, Alvarez CA, Roybal J, Goldsmith EJ, Tournier C, Kurie JM. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Mol Cell Biol. 2011 Nov.31(21):4270-4285. Pubmedid: 21896780. Pmcid: PMC3209326.
    • Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov.12(6):369-374. Pubmedid: 21729646. Pmcid: PMC3643693.
    • Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, Wistuba II, Lee JJ, Yen CJ, Su WC, Chang KY, Chang WC, Chou TC, Chou CK, Tsai CH, Hung MC. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One. 2011 Nov.6(6):e21428. Pubmedid: 21731744. Pmcid: PMC3121773.
    • Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2011 Mar.17(6):1490-1501. Pubmedid: 21163870. Pmcid: PMC3079395.
    • Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol. 2011 Mar.8(3):135-141. Pubmedid: 21364686.
    • Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, DiJoseph JF, Karnoub M, Huang S, Diesl V, Behrens C, Choe SE, Rios C, Gruzas J, Sridharan L, Dougher M, Kunz A, Hamann PR, Evans D, Armellino D, Khandke K, Marquette K, Tchistiakova L, Boghaert ER, Abraham RT, Wistuba II, Zhou BB. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res. 2011 Jun.71(12):4236-4246. Pubmedid: 21540235.
    • Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011 Jun.4(6):779-782. Pubmedid: 21636543.
    • Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology. 2011 Jun.152(6):2164-2173. Pubmedid: 21447628. Pmcid: PMC3100627.
    • Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, García-Franco CE, García-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res. 2011 Jun.17(12):4155-4166. Pubmedid: 21540238.
    • Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila). 2011 Jul.4(7):962-972. Pubmedid: 21733820. Pmcid: PMC3171137.
    • Tsuta K, Raso MG, Kalhor N, Liu DC, Wistuba II, Moran CA. Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung. Histopathology. 2011 Jan.58(2):276-285. Pubmedid: 21323953.
    • Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res. 2011 Jan.1(3):275-300. Pubmedid: 21938273. Pmcid: PMC3175764.
    • Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, Moran CA. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer. 2011 Jan.71(1):34-41. Pubmedid: 20462655.
    • Singh SP, Han L, Murali R, Solis L, Roth J, Ji L, Wistuba I, Kundra V. SSTR2-based reporters for assessing gene transfer into non-small cell lung cancer: evaluation using an intrathoracic mouse model. Hum Gene Ther. 2011 Jan.22(1):55-64. Pubmedid: 20653396. Pmcid: PMC3025187.
    • Stewart DJ, Behrens C, Roth J, Wistuba II. Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer. Lung Cancer. 2011 Feb.71(2):217-223. Pubmedid: 20627364. Pmcid: PMC2962880.
    • Gomperts BN, Spira A, Massion PP, Walser TC, Wistuba II, Minna JD, Dubinett SM. Evolving concepts in lung carcinogenesis. Sem Resp Crit Care M. 2011 Feb.32(1):32-43. Pubmedid: 21500122. Pmcid: PMC3423907.
    • Richards KL, Zhang B, Sun M, Dong W, Churchill J, Bachinski LL, Wilson CD, Baggerly KA, Yin G, Hayes DN, Wistuba II, Krahe R. Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer. 2011 Feb.117(3):606-617. Pubmedid: 20945327. Pmcid: PMC3023841.
    • Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb.6(2):244-285. Pubmedid: 21252716. Pmcid: PMC4513953.
    • Moussalli MJ, Wu Y, Zuo X, Yang XL, Wistuba II, Raso MG, Morris JS, Bowser JL, Minna JD, Lotan R, Shureiqi I. Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prev Res (Phila). 2011 Dec.4(12):1961-1972. Pubmedid: 21881028. Pmcid: PMC3232310.
    • Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec.6(12):2104-2111. Pubmedid: 21892101.
    • Tsuta K, Liu DC, Kalhor N, Wistuba II, Moran CA. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol. 2011 Aug.136(2):252-259. Pubmedid: 21757598.
    • Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug.71(16):5512-5521. Pubmedid: 21724587. Pmcid: PMC3159530.
    • Tsuta K, Kalhor N, Raso MG, Wistuba II, Moran CA. Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases. Hum Pathol. 2011 Apr.42(4):578-585. Pubmedid: 21329962.
    • Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011 Apr.17(8):2434-2443. Pubmedid: 21257719. Pmcid: PMC3078948.
    • Saintigny P, Wistuba II, Kim ES. Bronchioloalveolar carcinoma: a translational perspective. Oncology (Williston Park). 2010 Sep.24(10):907-8, 914. Pubmedid: 21138171.
    • Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010 Oct.467(7318):986-990. Pubmedid: 20962848. Pmcid: PMC3055799.
    • Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct.28(30):4609-4615. Pubmedid: 20855820. Pmcid: PMC2974341.
    • Chau NG, Kim ES, Wistuba I. The multidisciplinary approach to thymoma: combining molecular and clinical approaches. J Thorac Oncol. 2010 Oct.5(10 Suppl 4):S313-S317. Pubmedid: 20859125.
    • Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L, Fang B, Roth JA, Wistuba II, Swisher SG. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res. 2010 Nov.16(22):5522-5528. Pubmedid: 20930042. Pmcid: PMC3070287.
    • Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 2010 May.29(18):2616-2627. Pubmedid: 20154724. Pmcid: PMC3378055.
    • Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR. Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2010 May.19(5):1362-1372. Pubmedid: 20447926. Pmcid: PMC2880394.
    • Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun.9(6):1755-1763. Pubmedid: 20530716. Pmcid: PMC2913168.
    • Lee JJ, Feng L, Reshef DS, Sabichi AL, Williams B, Rinsurongkawong W, Wistuba II, Lotan R, Lippman SM. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun.3(6):738-744. Pubmedid: 20501862. Pmcid: PMC2881192.
    • Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010 Jul.16(14):3743-3753. Pubmedid: 20534738. Pmcid: PMC2920733.
    • Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba II. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res. 2010 Jan.16(1):34-44. Pubmedid: 20028769. Pmcid: PMC2811365.
    • Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol. 2010 Jan.133(1):133-140. Pubmedid: 20023269.
    • Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010 Feb.3(2):148-159. Pubmedid: 20103722. Pmcid: PMC4028718.
    • Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010 Feb.5(2):e9112. Pubmedid: 20161759. Pmcid: PMC2817751.
    • Ivan D, Prieto VG, Esmaeli B, Wistuba II, Tang X, Lazar AJ. Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma. J Cutan Pathol. 2010 Feb.37(2):231-236. Pubmedid: 19614729.
    • Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol. 2010 Dec.5(12):1894-1904. Pubmedid: 21124077. Pmcid: PMC3374718.
    • Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, Wistuba II, Minna JD, Mangelsdorf DJ. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 2010 Dec.7(12):e1000378. Pubmedid: 21179495. Pmcid: PMC3001894.
    • Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, Wistuba II, Minna JD. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010 Dec.70(23):9937-9948. Pubmedid: 21118965. Pmcid: PMC3058307.
    • Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 2010 Aug.70(16):6477-6485. Pubmedid: 20663904. Pmcid: PMC2922434.
    • Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE, Horvath S, Alavi M, Maresh EL, Chia D, Gower AC, Lenburg ME, Spira A, Solis LM, Wistuba II, Walser TC, Wallace WD, Dubinett SM, Goodglick L, Gomperts BN. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res. 2010 Aug.70(16):6639-6648. Pubmedid: 20710044. Pmcid: PMC2924777.
    • Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 Sep.15(17):5359-5368. Pubmedid: 19706809. Pmcid: PMC2893045.
    • Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, Feng L, Behrens C, Prudkin L, Miller YE, Lee JJ, Lippman SM, Hong WK, Wistuba II, Lee HY. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009 Sep.69(18):7439-7448. Pubmedid: 19738076. Pmcid: PMC2745504.
    • Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res. 2009 Sep.15(17):5317-5322. Pubmedid: 19706816.
    • Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HI. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009 Oct.8:91. Pubmedid: 19852844. Pmcid: PMC2776015.
    • Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, Varella-Garcia M, Vooder T, Wistuba II, Lam S, Brekken R, Toyooka S, Minna JD, Lam WL, Gazdar AF. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 2009 Oct.4(10):e7464. Pubmedid: 19826477. Pmcid: PMC2757721.
    • Jin N, Cho SN, Raso MG, Wistuba I, Smith Y, Yang Y, Kurie JM, Yen R, Evans CM, Ludwig T, Jeong JW, DeMayo FJ. Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development. 2009 Oct.136(19):3347-3356. Pubmedid: 19710174. Pmcid: PMC2739148.
    • Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov.2(11):931-941. Pubmedid: 19892663. Pmcid: PMC4243312.
    • Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009 Nov.8(21):2042-2050. Pubmedid: 19755855. Pmcid: PMC2833355.
    • Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009 May.22(5):668-678. Pubmedid: 19270647. Pmcid: PMC2675657.
    • Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009 Jun.15(11):3881-3888. Pubmedid: 19470736.
    • Uribe P, Wistuba II, Gonzalez S. Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am J Dermatopathxxx. 2009 Jun.31(4):354-363. Pubmedid: 19461239.
    • Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009 Jul.15(13):4423-4430. Pubmedid: 19531623.
    • Prudkin L, Tang X, Wistuba II. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol. 2009 Jan.4(1):139-141. Pubmedid: 19096324. Pmcid: PMC4512946.
    • Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009 Jan.106(2):474-479. Pubmedid: 19122144. Pmcid: PMC2626727.
    • Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila). 2009 Dec.2(12):1039-1049. Pubmedid: 19934338.
    • Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD, Wistuba II. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009 Aug.15(15):4829-4837. Pubmedid: 19622585. Pmcid: PMC3372920.
    • Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One. 2009 Aug.4(4):e5401. Pubmedid: 19404390. Pmcid: PMC2671160.
    • Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009 Aug.2(8):702-711. Pubmedid: 19638491. Pmcid: PMC3382104.
    • Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD, Pertsemlidis A. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 2009 Aug.7(8):1234-1243. Pubmedid: 19671678. Pmcid: PMC2741087.
    • Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr.27(12):2081-2090. Pubmedid: 19255316. Pmcid: PMC4881753.
    • Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol. 2009 Apr.40(4):443-453. Pubmedid: 18927348. Pmcid: PMC2660561.
    • Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008 Sep.68(17):6913-6921. Pubmedid: 18757405. Pmcid: PMC2874836.
    • Shivapurkar N, Stastny V, Okumura N, Girard L, Xie Y, Prinsen C, Thunnissen FB, Wistuba II, Czerniak B, Frenkel E, Roth JA, Liloglou T, Xinarianos G, Field JK, Minna JD, Gazdar AF. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res. 2008 Sep.68(18):7448-7456. Pubmedid: 18794132. Pmcid: PMC2849650.
    • Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, Lotan R. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Oct.14(19):6014-6022. Pubmedid: 18829480. Pmcid: PMC5108626.
    • Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct.455(7216):1069-1075. Pubmedid: 18948947. Pmcid: PMC2694412.
    • Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008 Nov.15(11):3147-3156. Pubmedid: 18754070.
    • Wistuba II, Meyerson M. Chromosomal deletions and progression of premalignant lesions: less is more. Cancer Prev Res (Phila). 2008 Nov.1(6):404-408. Pubmedid: 19138986.
    • Deus HF, Stanislaus R, Behrens C, Wistuba II, Minna JD, Garner HR, Swisher SG, Roth JA, Correa AM, Broom B, Coombes K, Almeida JS. Data driven semantic integration of translational lung cancer research at MDAnderson Cancer Center. Amia Annu Symp Proc. 2008 Nov.927. Pubmedid: 18999102.
    • Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One. 2008 May.3(5):e2220. Pubmedid: 18493606. Pmcid: PMC2376060.
    • Kuhn E, Wistuba II. Molecular pathology of thymic epithelial neoplasms. Hematol Oncol Clin North Am. 2008 Jun.22(3):443-455. Pubmedid: 18514126.
    • Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L, Wistuba II. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Jan.14(1):41-47. Pubmedid: 18172250. Pmcid: PMC2833352.
    • Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, Moghaddam S, Evans CM, Li H, Cai WW, Sato M, Minna JD, Wu H, Creighton CJ, Demayo FJ, Wistuba II, Kurie JM. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res. 2008 Feb.68(4):1119-1127. Pubmedid: 18281487. Pmcid: PMC2750029.
    • Massion PP, Zou Y, Chen H, Jiang A, Coulson P, Amos CI, Wu X, Wistuba I, Wei Q, Shyr Y, Spitz MR. Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med. 2008 Dec.178(11):1164-1172. Pubmedid: 18776155. Pmcid: PMC2720147.
    • McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res. 2008 Dec.14(23):7832-7837. Pubmedid: 19047111. Pmcid: PMC2614348.
    • Deus HF, Stanislaus R, Veiga DF, Behrens C, Wistuba II, Minna JD, Garner HR, Swisher SG, Roth JA, Correa AM, Broom B, Coombes K, Chang A, Vogel LH, Almeida JS. A Semantic Web management model for integrative biomedical informatics. PLoS One. 2008 Aug.3(8):e2946. Pubmedid: 18698353. Pmcid: PMC2491554.
    • Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, Wistuba II. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila). 2008 Aug.1(3):192-200. Pubmedid: 19138956. Pmcid: PMC3369271.
    • Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, Wistuba II, Kurie JM. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila). 2008 Aug.1(3):201-207. Pubmedid: 19138957. Pmcid: PMC3375599.
    • Seo HS, Liu DD, Bekele BN, Kim MK, Pisters K, Lippman SM, Wistuba II, Koo JS. Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. Cancer Res. 2008 Aug.68(15):6065-6073. Pubmedid: 18676828. Pmcid: PMC3058903.
    • Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther. 2008 Apr.7(4):952-960. Pubmedid: 18413809. Pmcid: PMC3378059.
    • Velasco A, Corvalan A, Wistuba II, Riquelme E, Chuaqui R, Majerson A, Leach FS. Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer. 2008 Apr.122(8):1774-1777. Pubmedid: 18076065.
    • Toyooka S, Matsuo K, Shigematsu H, Kosaka T, Tokumo M, Yatabe Y, Ichihara S, Inukai M, Suehisa H, Soh J, Kiura K, Fong KM, Lee H, Wistuba II, Gazdar AF, Mitsudomi T, Date H. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res. 2007 Oct.13(19):5763-5768. Pubmedid: 17908966.
    • Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, Roa I, Roa JC, Thomas MB. HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. Gastrointest Cancer Res. 2007 Nov.1(6):221-227. Pubmedid: 19262900. Pmcid: PMC2631213.
    • Mah V, Seligson DB, Li A, Márquez DC, Wistuba II, Elshimali Y, Fishbein MC, Chia D, Pietras RJ, Goodglick L. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 2007 Nov.67(21):10484-10490. Pubmedid: 17974992. Pmcid: PMC3581354.
    • Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007 May.13(10):2890-2896. Pubmedid: 17504988.
    • Riquelme E, Tang M, Baez S, Diaz A, Pruyas M, Wistuba II, Corvalan A. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett. 2007 May.250(1):100-106. Pubmedid: 17084965.
    • Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett. 2007 Mar.247(1):56-71. Pubmedid: 16644104. Pmcid: PMC3379713.
    • Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, Wistuba II, Roth JA, McGuire MJ, Brown KC. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007 Jun.67(12):5889-5895. Pubmedid: 17575158.
    • Kim SW, Cheon K, Kim CH, Yoon JH, Hawke DH, Kobayashi R, Prudkin L, Wistuba II, Lotan R, Hong WK, Koo JS. Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method. Cancer Res. 2007 Jul.67(14):6565-6573. Pubmedid: 17638865. Pmcid: PMC2958044.
    • Raso MG, Wistuba II. Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers. J Thorac Oncol. 2007 Jul.2(7 Suppl 3):S128-S135. Pubmedid: 17603309.
    • Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul.6(7):1962-1972. Pubmedid: 17620427.
    • Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol. 2007 Jan.170(1):366-376. Pubmedid: 17200208. Pmcid: PMC1762707.
    • Wistuba II. Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med. 2007 Feb.7(1):3-14. Pubmedid: 17311529.
    • Haigis KM, Wistuba II, Kurie JM. Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. Gene Dev. 2007 Feb.21(4):361-366. Pubmedid: 17322395.
    • Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal BB, Kurie JM. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem. 2007 Feb.282(6):3507-3519. Pubmedid: 17158870.
    • Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, Lee HY. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res. 2007 Dec.67(24):11630-11639. Pubmedid: 18089792.
    • Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec.450(7171):893-898. Pubmedid: 17982442. Pmcid: PMC2538683.
    • Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, Hanna AE, Liu D, Girard L, Kim YH, Pollack JR, Minna JD, Wistuba II, Kurie JM. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene. 2007 Apr.26(18):2658-2666. Pubmedid: 17057737.
    • Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007 Apr.4(4):e125. Pubmedid: 17455987. Pmcid: PMC1876407.
    • Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, Thomas M, Vasquez KM, DiGiovanni J. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007 Apr.67(8):3794-3800. Pubmedid: 17440093.
    • Prudkin L, Wistuba II. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann Diagn Pathol. 2006 Oct.10(5):306-315. Pubmedid: 16979526.
    • Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol. 2006 Nov.1(9 Suppl):S13-S19. Pubmedid: 17409995.
    • Wislez M, Beer DG, Wistuba I, Cadranel J, Saijo N, Johnson BE. Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. J Thorac Oncol. 2006 Nov.1(9 Suppl):S8-12. Pubmedid: 17410000.
    • Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar.1(3):231-239. Pubmedid: 17409862.
    • Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006 Dec.107(11):2637-2646. Pubmedid: 17078054.
    • Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006 Dec.66(23):11194-11206. Pubmedid: 17145864.
    • Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol. 2006 Dec.1:331-348. Pubmedid: 18039118.
    • Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Dec.12(24):7329-7338. Pubmedid: 17189404.
    • Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, Mao L, Wistuba I, Strieter RM, Kurie JM. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 2006 Apr.66(8):4198-4207. Pubmedid: 16618742.
    • Guillaud M, le Riche JC, Dawe C, Korbelik J, Coldman A, Wistuba II, Park IW, Gazdar A, Lam S, MacAulay CE. Nuclear morphometry as a biomarker for bronchial intraepithelial neoplasia: correlation with genetic damage and cancer development. Cytometry A. 2005 Sep.63(1):34-40. Pubmedid: 15614828.
    • Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005 Sep.65(17):7568-7572. Pubmedid: 16140919.
    • Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnisen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005 May.23(14):3279-3287. Pubmedid: 15886315.
    • Sabloff BS, Wistuba II, Erasmus JJ. Cystic bronchioloalveolar cell carcinoma. J Thorac Imaging. 2005 May.20(2):110-114. Pubmedid: 15818211.
    • Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005 Mar.65(5):1642-1646. Pubmedid: 15753357.
    • Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005 Mar.97(5):339-346. Pubmedid: 15741570.
    • Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba II, Meltzer SJ, Gazdar AF. Aberrant methylation of Reprimo in human malignancies. Int J Cancer. 2005 Jul.115(4):503-510. Pubmedid: 15700311.
    • Moreno M, Pimentel F, Gazdar AF, Wistuba II, Miquel JF. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol. 2005 Jul.4(3):192-199. Pubmedid: 16177659.
    • Wistuba II. Histologic evaluation of bronchial squamous lesions: any role in lung cancer risk assessment?. Clin Cancer Res. 2005 Feb.11(4):1358-1360. Pubmedid: 15746032.
    • Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res. 2005 Dec.65(24):11478-11485. Pubmedid: 16357156.
    • Uribe P, Wistuba II, Solar A, Balestrini C, Perez-Cotapos ML, Gonzalez S. Comparative analysis of loss of heterozygosity and microsatellite instability in adult and pediatric melanoma. Am J Dermatopathxxx. 2005 Aug.27(4):279-285. Pubmedid: 16121045.
    • Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res. 2005 Apr.65(8):3226-3235. Pubmedid: 15833854.
    • Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004 Sep.4(9):695-706. Pubmedid: 15343276.
    • Takahashi T, Shivapurkar N, Riquelme E, Shigematsu H, Reddy J, Suzuki M, Miyajima K, Zhou X, Bekele BN, Gazdar AF, Wistuba II. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res. 2004 Sep.10(18 Pt 1):6126-6133. Pubmedid: 15447999.
    • Sabloff BS, Truong MT, Wistuba II, Erasmus JJ. Bronchioalveolar cell carcinoma: radiologic appearance and dilemmas in the assessment of response. Clin Lung Cancer. 2004 Sep.6(2):108-112. Pubmedid: 15476596.
    • Velasco A, Riquelme E, Schultz M, Wistuba II, Villarroel L, Pizarro J, Berlin A, Ittmann M, Koh MS, Leach FS. Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther. 2004 Oct.3(10):977-982. Pubmedid: 15467433.
    • Velasco A, Riquelme E, Schultz M, Wistuba II, Villarroel L, Koh MS, Leach FS. Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol Ther. 2004 Nov.3(11):1152-1158. Pubmedid: 15492498.
    • Goldenberg D, Rosenbaum E, Argani P, Wistuba II, Sidransky D, Thuluvath PJ, Hidalgo M, Califano J, Maitra A. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol. 2004 Nov.17(11):1386-1391. Pubmedid: 15181454.
    • Kronberg U, López-Kostner F, Soto G, Zúñiga A, Wistuba I, Miranda V, Pinto E, Viviani P, Marshall G. Detection of lymphatic micrometastases in patients with stages I and II colorectal cancer: impact on five-year survival. Dis Colon Rectum. 2004 Jul.47(7):1151-1157. Pubmedid: 15164250.
    • Tang M, Baez S, Pruyas M, Diaz A, Calvo A, Riquelme E, Wistuba II. Mitochondrial DNA mutation at the D310 (displacement loop) mononucleotide sequence in the pathogenesis of gallbladder carcinoma. Clin Cancer Res. 2004 Feb.10(3):1041-1046. Pubmedid: 14871983.
    • Tang X, Wu W, Sun SY, Wistuba II, Hong WK, Mao L. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells. Mol Cancer Res. 2004 Dec.2(12):685-691. Pubmedid: 15634757.
    • Fullerton DA, López F, Avendaño R, Aparicio R, Wistuba I. [Atypical presentation of a colorectal carcinoma]. Rev Med Chil. 2004 Aug.132(8):985-988. Pubmedid: 15478301.
    • Wistuba II, Behrens C, Albores-Saavedra J, Delgado R, Lopez F, Gazdar AF. Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma. Clin Cancer Res. 2003 Sep.9(10 Pt 1):3615-3619. Pubmedid: 14506148.
    • Tang M, Pires Y, Schultz M, Duarte I, Gallegos M, Wistuba II. Microsatellite analysis of synchronous and metachronous tumors: a tool for double primary tumor and metastasis assessment. Diagn Mol Pathol. 2003 Sep.12(3):151-159. Pubmedid: 12960697.
    • Uribe P, Wistuba II, González S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathxxx. 2003 Oct.25(5):365-370. Pubmedid: 14501284.
    • House MG, Wistuba II, Argani P, Guo M, Schulick RD, Hruban RH, Herman JG, Maitra A. Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol. 2003 Oct.10(8):882-889. Pubmedid: 14527906.
    • Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Schulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R, Wistuba II, Varma R, Hawthorne L, Geradts J, Argani P, Maitra A. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol. 2003 Jul.163(1):217-229. Pubmedid: 12819026. Pmcid: PMC1868162.
    • Miquel JF, Moreno M, Amigo L, Molina H, Mardones P, Wistuba II, Rigotti A. Expression and regulation of scavenger receptor class B type I (SR-BI) in gall bladder epithelium. Gut. 2003 Jul.52(7):1017-1024. Pubmedid: 12801960. Pmcid: PMC1773711.
    • Wistuba II, Gazdar AF. Characteristic genetic alterations in lung cancer. Methods Mol Med. 2003 Apr.74:3-28. Pubmedid: 12415683.
    • Wistuba II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene. 2002 Oct.21(48):7298-7306. Pubmedid: 12379874.
    • Wistuba II, Ashfaq R, Maitra A, Alvarez H, Riquelme E, Gazdar AF. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol. 2002 Jun.160(6):2073-2079. Pubmedid: 12057912. Pmcid: PMC1850840.
    • Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res. 2002 Jul.8(7):2292-2297. Pubmedid: 12114433.
    • Field J, Brambilla C, Caporaso N, Flahault A, Henschke C, Herman J, Hirsch F, Lachmann P, Lam S, Maier S, Montuenga L, Mulshine J, Murphy M, Pullen J, SpitzM, Tockman M, Tyndale R, Wistuba I, Youngson J. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol. 2002 Aug.21(2):369-373. Pubmedid: 12118333.
    • Wistuba II, Maitra A, Carrasco R, Tang M, Troncoso P, Minna JD, Gazdar AF. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Brit J Cancer. 2002 Aug.87(4):432-440. Pubmedid: 12177780. Pmcid: PMC2376134.
    • Huang J, Behrens C, Wistuba II, Gazdar AF, Jagirdar J. Clonality of combined tumors. Arch Pathol Lab Med. 2002 Apr.126(4):437-441. Pubmedid: 11900568.
    • Wistuba II, Tang M, Maitra A, Alvarez H, Troncoso P, Pimentel F, Gazdar AF. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res. 2001 May.61(9):3795-3800. Pubmedid: 11325854.
    • Maitra A, Wistuba II, Gazdar AF. Microdissection and the study of cancer pathways. Curr Mol Med. 2001 Mar.1(1):153-162. Pubmedid: 11899240.
    • Wistuba II. [Molecular pathology: applications of molecular biology in pathological anatomy]. Rev Med Chil. 2001 Jul.129(7):791-804. Pubmedid: 11552450.
    • Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF, Minna JD. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol. 2001 Jul.159(1):119-130. Pubmedid: 11438460. Pmcid: PMC1850416.
    • Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol. 2001 Dec.5(6):321-329. Pubmedid: 11745069.
    • Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001 Apr.28(2 Suppl 4):3-13. Pubmedid: 11479891.
    • Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. CA-Cancer J Clin. 2001.51(6):349-364. Pubmedid: 11760569.
    • Behrens C, Travis LB, Wistuba II, Davis S, Maitra A, Clarke EA, Lynch CF, Glimelius B, Wiklund T, Tarone R, Gazdar AF. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev. 2000 Oct.9(10):1027-1035. Pubmedid: 11045784.
    • Zöchbauer-Müller S, Wistuba II, Minna JD, Gazdar AF. Fragile histidine triad (FHIT) gene abnormalities in lung cancer. Clin Lung Cancer. 2000 Nov.2(2):141-145. Pubmedid: 14731325.
    • Shivapurkar N, Wiethege T, Wistuba II, Milchgrub S, Muller KM, Gazdar AF. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer. 2000 Mar.85(5):743-745. Pubmedid: 10699959.
    • Larramendy ML, Lushnikova T, Björkqvist AM, Wistuba II, Virmani AK, Shivapurkar N, Gazdar AF, Knuutila S. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogen. 2000 Jun.119(2):132-138. Pubmedid: 10867149.
    • Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000 Jul.6(7):2604-2610. Pubmedid: 10914700. Pmcid: PMC5164924.
    • Milchgrub S, Wistuba II, Kim BK, Rutherford C, Urban J, Cruz PD, Gazdar AF. Molecular identification of metastatic cancer to the skin using laser capture microdissection: a case report. Cancer. 2000 Feb.88(4):749-754. Pubmedid: 10679642.
    • Wistuba II, Tomlinson GE, Behrens C, Virmani A, Geradts J, Blum JL, Minna JD, Gazdar AF. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. Gene Chromosome Canc. 2000 Aug.28(4):359-369. Pubmedid: 10862044.
    • Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna JD. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000 Apr.60(7):1949-1960. Pubmedid: 10766185.
    • Wistuba II, Gazdar AF. Molecular pathology of lung cancer. Verh Dtsch Ges Pathol. 2000.84:96-105. Pubmedid: 11217455.
    • Maitra A, Wistuba II, Gibbons D, Gazdar AF, Albores-Saavedra J. Allelic losses at chromosome 3p are seen in human papilloma virus 16 associated transitional cell carcinoma of the cervix. Gynecol Oncol. 1999 Sep.74(3):361-368. Pubmedid: 10479494.
    • Wistuba II, Syed S, Behrens C, Duong M, Milchgrub S, Muller CY, Jagirdar J, Gazdar AF. Comparison of molecular changes in cervical intraepithelial neoplasia in HIV-positive and HIV-indeterminate subjects. Gynecol Oncol. 1999 Sep.74(3):519-526. Pubmedid: 10479524.
    • Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna JD, Gazdar AF. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst. 1999 Nov.91(21):1863-1868. Pubmedid: 10547393.
    • Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, Minna JD, Gazdar AF. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res. 1999 May.5(5):991-1000. Pubmedid: 10353731.
    • Euhus DM, Maitra A, Wistuba II, Alberts A, Albores-Saavedra J, Gazdar AF. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer. J Surg Res. 1999 May.83(1):13-18. Pubmedid: 10210636.
    • Scurry J, Flowers L, Wistuba I, Vanin K, Mulvany N, Reyes H, Gazdar A. Human papillomavirus presence and survival. Int J Gynecol Cancer. 1999 Mar.9(2):173-174. Pubmedid: 11240763.
    • Wistuba II, Behrens C, Gazdar AF. Pathogenesis of non-AIDS-defining cancers: a review. Aids Patient Care Stds. 1999 Jul.13(7):415-426. Pubmedid: 10870595.
    • Ramnani DM, Wistuba II, Behrens C, Gazdar AF, Sobin LH, Albores-Saavedra J. K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Cancer. 1999 Jul.86(1):14-21. Pubmedid: 10391558.
    • Flowers LC, Wistuba II, Scurry J, Muller CY, Ashfaq R, Miller DS, Minna JD, Gazdar AF. Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. J Soc Gynecol Investig. 1999 Jul.6(4):213-221. Pubmedid: 10486784.
    • Shivapurkar N, Virmani AK, Wistuba II, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res. 1999 Jan.5(1):17-23. Pubmedid: 9918198.
    • Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 1999 Jan.18(3):643-650. Pubmedid: 9989814.
    • Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol. 1999 Jan.30(1):21-25. Pubmedid: 9923922.
    • Wistuba II, Thomas B, Behrens C, Onuki N, Lindberg G, Albores-Saavedra J, Gazdar AF. Molecular abnormalities associated with endocrine tumors of the uterine cervix. Gynecol Oncol. 1999 Jan.72(1):3-9. Pubmedid: 9889022.
    • Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, Hasleton P, Gazdar AF. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 1999 Feb.85(3):600-607. Pubmedid: 10091733.
    • Shivapurkar N, Wiethege T, Wistuba II, Salomon E, Milchgrub S, Muller KM, Churg A, Pass H, Gazdar AF. Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem. 1999 Dec.76(2):181-188. Pubmedid: 10618635.
    • Euhus DM, Maitra A, Wistuba II, Ashfaq R, Alberts A, Gibbons D, Gazdar AF. Use of archival fine-needle aspirates for the allelotyping of tumors. Cancer. 1999 Dec.87(6):372-379. Pubmedid: 10603191.
    • Maitra A, Tavassoli FA, Albores-Saavedra J, Behrens C, Wistuba II, Bryant D, Weinberg AG, Rogers BB, Saboorian MH, Gazdar AF. Molecular abnormalities associated with secretory carcinomas of the breast. Hum Pathol. 1999 Dec.30(12):1435-1440. Pubmedid: 10667421.
    • Shivapurkar N, Sood S, Wistuba II, Virmani AK, Maitra A, Milchgrub S, Minna JD, Gazdar AF. Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res. 1999 Aug.59(15):3576-3580. Pubmedid: 10446964.
    • Maitra A, Wistuba II, Virmani AK, Sakaguchi M, Park I, Stucky A, Milchgrub S, Gibbons D, Minna JD, Gazdar AF. Enrichment of epithelial cells for molecular studies. Nat Med. 1999 Apr.5(4):459-463. Pubmedid: 10202940.
    • Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 1999 Apr.59(8):1973-1979. Pubmedid: 10213509.
    • Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg. 1999.6(3):237-244. Pubmedid: 10526058.
    • Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, Milchgrub S, Brezinschek R, Virmani A, Gazdar AF, Minna JD. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 1998 Sep.17(12):1557-1565. Pubmedid: 9794233.
    • Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. Jama. 1998 May.279(19):1554-1559. Pubmedid: 9605900.
    • Muller CY, O'Boyle JD, Fong KM, Wistuba II, Biesterveld E, Ahmadian M, Miller DS, Gazdar AF, Minna JD. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type. J Natl Cancer Inst. 1998 Mar.90(6):433-439. Pubmedid: 9521167.
    • Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, Duh FM, Gazdar AF, Lerman MI, Minna JD. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene. 1998 Jun.16(24):3151-3157. Pubmedid: 9671394.
    • Colby TV, Wistuba II, Gazdar A. Precursors to pulmonary neoplasia. Adv Anat Pathol. 1998 Jul.5(4):205-215. Pubmedid: 9859753.
    • Wistuba II, Behrens C, Milchgrub S, Syed S, Ahmadian M, Virmani AK, Kurvari V, Cunningham TH, Ashfaq R, Minna JD, Gazdar AF. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res. 1998 Dec.4(12):2931-2938. Pubmedid: 9865903.
    • Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, Ashfaq R, Leitch AM, Minna JD, Shay JW. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998 Dec.78(6):766-774. Pubmedid: 9833771.
    • Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW, Minna JD, Gazdar AF. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 1998 Aug.58(15):3237-3242. Pubmedid: 9699648.
    • Lininger RA, Wistuba I, Gazdar A, Koenig C, Tavassoli FA, Albores-Saavedra J. Human papillomavirus type 16 is detected in transitional cell carcinomas and squamotransitional cell carcinomas of the cervix and endometrium. Cancer. 1998 Aug.83(3):521-527. Pubmedid: 9690545.
    • Yamamoto Y, Wistuba II, Kishimoto Y, Virmani AK, Vuitch F, Albores-Saavedra J, Gazdar AF. DNA analysis at p53 locus in adenoid cystic carcinoma: comparison of molecular study and p53 immunostaining. Pathol Int. 1998 Apr.48(4):273-280. Pubmedid: 9648155.
    • Yamamoto Y, Kishimoto Y, Wistuba II, Virmani AK, Vuitch F, Gazdar AF, Albores-Saavedra J. DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: comparison of molecular study and p53 immunostaining. Pathol Int. 1998 Apr.48(4):265-272. Pubmedid: 9648154.
    • Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava S, Minna JD, Gazdar AF. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst. 1997 Sep.89(18):1366-1373. Pubmedid: 9308707. Pmcid: PMC5193483.
    • Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD, Gazdar AF. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 1997 Sep.57(17):3664-3668. Pubmedid: 9288768.
    • Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest. 1997 Oct.100(8):2133-2137. Pubmedid: 9329980. Pmcid: PMC508406.
    • Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW, Gazdar AF. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res. 1997 Jun.57(12):2373-2377. Pubmedid: 9192812.
    • Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res. 1997 Jun.57(11):2256-2267. Pubmedid: 9187130.
    • Ossa G, Wistuba I, Illesca V, Reydet P. [Invasive extrapulmonary infections due to Streptococcus pneumoniae. Report of three fatal cases and review]. Rev Med Chil. 1997 Feb.125(2):200-208. Pubmedid: 9430941.
    • Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, Gazdar AF. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 1997 Aug.57(15):3154-3158. Pubmedid: 9242443.
    • Yamamoto Y, Virmani AK, Wistuba II, McIntire D, Vuitch F, Albores-Saavedra J, Gazdar AF. Loss of heterozygosity and microsatellite alterations in p53 and RB genes in adenoid cystic carcinoma of the salivary glands. Hum Pathol. 1996 Nov.27(11):1204-1210. Pubmedid: 8912832.
    • Wistuba I, Capurro I. [Epidermoid carcinoma of the cervix uteri: molecular abnormalities of p53 and rb genes]. Rev Med Chil. 1996 May.124(5):553-560. Pubmedid: 9035506.
    • Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol. 1996 Apr.27(4):360-365. Pubmedid: 8617479.
    • Wistuba I, Roa I, Araya JC, Villaseca M, Capurro I, Chávez F. [Proliferating cell nuclear antigen in cervical cancer and precursor lesions]. Rev Med Chil. 1995 Sep.123(9):1077-1083. Pubmedid: 8728730.
    • Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J, Gazdar AF. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 1995 Jun.55(12):2511-2515. Pubmedid: 7780959.
    • Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Gómez A, Silva J. [Laparoscopic cholecystectomy makes difficult the analysis of gallbladder mucosa. Morphometric study]. Rev Med Chil. 1994 Sep.122(9):1015-1020. Pubmedid: 7597331.
    • Araya JC, Roa I, Hebel E, Wistuba I, Villaseca MA, Yañez M. [Proliferating cell nuclear antigen (PCNA) in patients with malabsorption syndrome: comparative study with morphometric parameters]. Rev Med Chil. 1994 Oct.122(10):1134-1139. Pubmedid: 7659878.
    • Araya JC, Roa I, Wistuba I, Villaseca MA, Contreras E, Olcese A, Danton A. [Expression of p29, estrogen receptor related protein in primary breast carcinoma. Methodological, anatomoclinical, and DNA content analysis]. Rev Med Chil. 1994 Oct.122(10):1140-1146. Pubmedid: 7659879.
    • Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Burgos L. [Gallbladder cancer in the IX Region of Chile. Impact of the anatomopathological study of 474 cases]. Rev Med Chil. 1994 Nov.122(11):1248-1256. Pubmedid: 7659894.
    • Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Ferreira A, Gómez A. [Determination of DNA content using cytophotometry in nuclear suspension conserved for prolonged periods (preliminary study)]. Rev Med Chil. 1994 Mar.122(3):253-258. Pubmedid: 7809514.
    • Araya JC, Roa I, Wistuba I, Villaseca MA, Contreras E, Olcese A, Danton A, Watanabe H. [Breast cancer and flow cytometry: comparative study of DNA ploidy pattern with clinicopathological parameters]. Rev Med Chil. 1994 Jun.122(6):643-652. Pubmedid: 7732208.
    • Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, de Aretxabala X. [Gallbladder carcinoma: expression of the c-myc and ras-p-21 oncogene products]. Rev Med Chil. 1994 Jul.122(7):754-759. Pubmedid: 7732224.
    • De Aretxabala X, Roa I, Araya JC, Burgos L, Flores P, Wistuba I, Villaseca MA, Sotomayor F, Roa JC. Gallbladder cancer in patients less than 40 years old. Br J Surg. 1994 Jan.81(1):111. Pubmedid: 8313082.
    • Wistuba I, Roa I, Araya J, Villaseca M, Chávez F, Capurro I. [Immunohistochemical expression of epidermal growth factor receptor (EGFR) in epidermoid carcinoma of the cervix uteri and its precursor lesions]. Rev Chil Obstet Ginecol. 1994.59(2):116-122. Pubmedid: 7659795.
    • Wistuba I, Roa I, Araya JC, Villaseca M, Capurro I, Rojo J. [Nucleolar organizer regions in uterine cervical cancer and its precursor epithelial lesions]. Rev Med Chil. 1993 Oct.121(10):1110-1117. Pubmedid: 8191113.
    • Araya JC, Roa I, Mano H, Yamamoto M, Wistuba I, Villaseca MA, de Aretxabala X, Ohta T, Burgos L. [Mutagen extraction from bile of patients with inflammatory biliary pathology: Ames test using blue rayon]. Rev Med Chil. 1993 Nov.121(11):1245-1251. Pubmedid: 8191130.
    • Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, De Aretxabala X. DNA content in gallbladder carcinoma: a flow cytometric study of 96 cases. Histopathology. 1993 Nov.23(5):459-464. Pubmedid: 8314220.
    • Wistuba I, Arcil G, Farrú O, Chuaqui B. [Idiopathic asymmetric heart hypertrophy in a newborn infant]. Pathologe. 1993 May.14(3):127-130. Pubmedid: 8516269.
    • Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Busel D, Burgos L. [Epithelial lesions associated with gallbladder carcinoma. A methodical study of 32 cases]. Rev Med Chil. 1993 Jan.121(1):21-29. Pubmedid: 8235160.
    • Roa I, Araya J, Shiraishi T, Yatani R, Villaseca M, Wistuba I, De-Aretxabala X. Proliferating cell nuclear antigen in gallbladder carcinoma. Histopathology. 1993 Aug.23(2):179-183. Pubmedid: 8104857.
    • Roa I, Villaseca M, Wistuba I, Araya JC, De Aretxabala X. [Determination of DNA content by means of cytophotometry. Technical and methodological considerations and its application in tumor pathology]. Rev Med Chil. 1993 Aug.121(8):897-902. Pubmedid: 8296097.
    • Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, de Aretxabala X. [Stomach and gallbladder cancer. Analysis of cell cycle phases by means of flow cytometry]. Rev Med Chil. 1993 Aug.121(8):881-888. Pubmedid: 8296095.
    • Wistuba I, Roa I, Villaseca MA, Araya JC, Capurro I. [Cervix uteri cancer: determination of DNA content by means of cytophotometry]. Rev Med Chil. 1993 Aug.121(8):873-879. Pubmedid: 8296094.
    • Roa I, Araya JC, de Aretxabala X, Villaseca MA, Wistuba I, Burgos L. [Laparoscopic cholecystectomy makes the histopathological study of the gallbladder mucosa difficult]. Rev Med Chil. 1993 Apr.121(4):458-459. Pubmedid: 8272623.
    • Roa I, Araya JC, Shiraisch T, Yatani R, Wistuba I, Villaseca M, de Aretxabala X. [Gallbladder cancer: immunohistochemical expression of CA-19-9, epithelial membrane antigen, dupan-2 and carcinoembryonic antigen]. Rev Med Chil. 1992 Nov.120(11):1218-1226. Pubmedid: 1340939.
    • Roa I, Araya JC, de Aretxabala X, Wistuba I, Villaseca M, Saito K, Nakamura K. [Gastric cancer: epidermal growth factor and epidermal growth factor receptor]. Rev Med Chil. 1992 Jan.120(1):5-12. Pubmedid: 1305311.
    • de Aretxabala X, Roa I, Burgos L, Araya JC, Fonseca L, Wistuba I, Flores P. Gallbladder cancer in Chile. A report on 54 potentially resectable tumors. Cancer. 1992 Jan.69(1):60-65. Pubmedid: 1727676.
    • Capurro I, Jorquera J, Rojo JA, Wistuba I. [2 rare cases of a presentation of endometrial cancer]. Rev Chil Obstet Ginecol. 1992 Feb.57(5):351-355. Pubmedid: 1342466.
    • Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, de Aretxabala X. [Immunohistochemical demonstration of pepsinogens I and II in the gallbladder]. Rev Med Chil. 1992 Dec.120(12):1351-1358. Pubmedid: 1343374.
    • de Aretxabala X, Araya JC, Flores P, Roa I, Fernández E, Wistuba I, Villaseca MA, Huenchullán I, Arredondo G, Flores M. [Characteristics of gastric cancer in the IX region of Chile]. Rev Med Chil. 1992 Apr.120(4):407-414. Pubmedid: 1340570.
    • Araya JC, Roa I, Wistuba I, Villaseca M, de Aretxabala X. [Stomach neoplasms in the IX Region of Chile: comparison of the anatomo-pathological study of lymph node emptying in 2 periods]. Rev Med Chil. 1991 May.119(5):546-552. Pubmedid: 1844294.
    • Roa I, Araya JC, de Aretxabala X, Wistuba I, Villaseca M, Saito K, Nakamura K. [Advanced stomach neoplasms: expression of the fixation index of bromodeoxyuridine in vivo]. Rev Med Chil. 1991 Jun.119(6):637-646. Pubmedid: 1844367.
    • Roa I, Araya JC, de Aretxabala X, Wistuba I, Villaseca M. [Nucleolus organizer regions and ploidy pattern of DNA in stomach neoplasms]. Rev Med Chil. 1991 Jun.119(6):647-651. Pubmedid: 1844368.
    • Roa I, Araya JC, Wistuba I, De Aretxabala X, Salinas C, Mauriz A, Villaseca M. [Immunohistochemical expression of the carcinoembryonic antigen in gallbladder cancer]. Rev Med Chil. 1991 Feb.119(2):129-136. Pubmedid: 1824154.
    • Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X. [Lithiasis of gallbladder in the IX region. Study of the autopsies in a zone with a high proportion of Mapuche population]. Rev Med Chil. 1991 Dec.119(12):1367-1371. Pubmedid: 9723092.
    • de Aretxabala X, Roa I, Burgos L, Araya JC, Wistuba I, Villaseca MA, Fonseca L, Flores P, Sotomayor F. [Inapparent cancer of the gallbladder]. Rev Med Chil. 1991 Aug.119(8):881-886. Pubmedid: 1844768.
    • Roa I, Araya JC, Wistuba I, de Aretxabala X. [Gallbladder cancer: anatomic and anatomo-pathologic considerations]. Rev Med Chil. 1990 May.118(5):572-579. Pubmedid: 2293279.
    • Wistuba I, Gonzalez S. Eosinophilic globules in pigmented spindle cell nevus. Am J Dermatopathxxx. 1990 Jun.12(3):268-271. Pubmedid: 1693819.
    • de Aretxabala X, Wistuba I, Burgos L, Roa I, Araya JC, Fonseca L, Flores P. [Association of gallbladder and Vater's ampulla neoplasms. Report of a case]. Rev Med Chil. 1990 Jul.118(7):783-786. Pubmedid: 2131528.
    • Roa I, Aray JC, de Aretxabala X, Wistuba I, Burgos L. [The pathological findings in patients reoperated on for gallbladder cancer]. Rev Med Chil. 1990 Feb.118(2):153-157. Pubmedid: 2152714.
    • Roa I, Araya JC, Wistuba I, De Aretxabala X, Mauriz A, Cea M. [In situ and invasive cancer of the gallbladder: nucleolar organizer regions]. Rev Med Chil. 1990 Apr.118(4):369-372. Pubmedid: 1723212.
    • Araya JC, Roa I, Wistuba I, de Aretxabala X. [Neoplasms of Vater's papilla: study of nucleolar organizer regions]. Rev Med Chil. 1990 Apr.118(4):373-381. Pubmedid: 1723213.
    • Roa I, Araya JC, de Aretxabala X, Salinas C, Wistuba I. [Gallbladder pathology in Temuco, IX Region]. Rev Med Chil. 1989 Aug.117(8):889-894. Pubmedid: 2519448.

  • Grants

    • Title: Cancer Immune Monitoring and Analysis Centers (CIMACs) for the Cancer MoonshotSM Program (U24)".
      Award Number: 5U24CA224285-04
      Sponsor: National Cancer Institute (NCI)
      Wistuba, I. (PD/PI)
    • Title: SWOG Network Group Operations Center of the NCTN
      Award Number: 5U10CA180888-11 REVISED
      Sponsor: National Cancer Institute (NCI)
      Wistuba, I. (PD/PI)
    • Title: Characterization of Immunohistochemical (IHC) target expression profile in KRAS-mutated cancers.
      Award Number: 26-0044
      Sponsor: Zymeworks, Inc.
      Wistuba, I. (PD/PI)

  • Patient Comments

    Overall Satisfaction

    0

    0 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey 

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    Learn more about our patient comments

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 10 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor

Cambiar el idioma

Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al 1-888-663-3488.

Gracias.

 

 

 

 

Cancel | Cancelar OK